139 related articles for article (PubMed ID: 9706132)
1. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene.
Hwang RF; Gordon EM; Anderson WF; Parekh D
Surgery; 1998 Aug; 124(2):143-50; discussion 150-1. PubMed ID: 9706132
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir.
Yang L; Hwang R; Pandit L; Gordon EM; Anderson WF; Parekh D
Ann Surg; 1996 Sep; 224(3):405-14; discussion 414-7. PubMed ID: 8813269
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments].
Bouvet M; Bold RJ; Lee J; Evans DB; Abbruzzese JL; Chiao PJ; McConkey DJ; Chandra J; Chada S; Fang B; Roth JA
Ann Surg Oncol; 1998 Dec; 5(8):681-8. PubMed ID: 9869513
[TBL] [Abstract][Full Text] [Related]
5. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.
Péron JM; Bureau C; Gourdy P; Lulka H; Souque A; Calippe B; Selves J; Al Saati T; Bernad J; Cordelier P; Couderc B; Pradayrol L; Pipy B; Buscail L; Vinel JP
Gut; 2007 Jan; 56(1):107-14. PubMed ID: 16891358
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
Fujiwara T; Cai DW; Georges RN; Mukhopadhyay T; Grimm EA; Roth JA
J Natl Cancer Inst; 1994 Oct; 86(19):1458-62. PubMed ID: 8089864
[TBL] [Abstract][Full Text] [Related]
8. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells.
Skotzko M; Wu L; Anderson WF; Gordon EM; Hall FL
Cancer Res; 1995 Dec; 55(23):5493-8. PubMed ID: 7585620
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.
Ghaneh P; Greenhalf W; Humphreys M; Wilson D; Zumstein L; Lemoine NR; Neoptolemos JP
Gene Ther; 2001 Feb; 8(3):199-208. PubMed ID: 11313791
[TBL] [Abstract][Full Text] [Related]
11. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
13. Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis.
Weinberg WC; Montano NE; Deng C
Oncogene; 1997 Aug; 15(6):685-90. PubMed ID: 9264409
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ.
Wang TJ; Huang MS; Hong CY; Tse V; Silverberg GD; Hsiao M
Biochem Biophys Res Commun; 2001 Sep; 287(1):173-80. PubMed ID: 11549271
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53.
Guo H; Liu T; Gao J
Chin Med J (Engl); 1998 Dec; 111(12):1102-6. PubMed ID: 11263374
[TBL] [Abstract][Full Text] [Related]
16. p53 gene transfer does not enhance E2F-1-mediated apoptosis in human colon cancer cells.
Draus JM; Elliott MJ; Atienza C; Stilwell A; Wong SL; Dong Y; Yang H; McMasters KM
Exp Mol Med; 2001 Dec; 33(4):209-19. PubMed ID: 11795482
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
Kim J; Hwang ES; Kim JS; You EH; Lee SH; Lee JH
Cancer Gene Ther; 1999; 6(2):172-8. PubMed ID: 10195884
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
19. Preclinical study of adenoviral p53 gene therapy for esophageal cancer.
Shimada H; Shimizu T; Ochiai T; Liu TL; Sashiyama H; Nakamura A; Matsubara H; Gunji Y; Kobayashi S; Tagawa M; Sakiyama S; Hiwasa T
Surg Today; 2001; 31(7):597-604. PubMed ID: 11495154
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
